Intimacy during and after cancer treatment

Scale of the problem

Sexual difficulty is among the most common and most persistent late effects of cancer treatment, and among the least addressed. Studies consistently find that 40–100 percent of survivors report sexual problems depending on cancer type, and that most were never asked about it by their oncology team. It frequently persists years after treatment ends and after other side effects resolve.

Raising it is not vanity and not a low priority. Sexual function is part of survivorship care, and it is a legitimate thing to ask about at any appointment.

What different treatments do

Surgery. Pelvic surgery can damage nerves and blood vessels. Radical prostatectomy causes erectile dysfunction in a substantial proportion even with nerve-sparing technique, and causes loss of ejaculation in all cases. Hysterectomy can shorten the vagina and alter sensation. Mastectomy affects chest and nipple sensation and body image. Stoma formation changes body image and requires practical adaptation.

Radiotherapy. Pelvic radiotherapy causes vaginal stenosis, dryness, fibrosis and loss of elasticity, developing over months after treatment. In men, it causes progressive erectile dysfunction over 1–2 years as small vessels are damaged.

Chemotherapy. Mucositis, dryness, early menopause including permanent ovarian failure, fatigue, neuropathy affecting genital sensation, hair loss and altered body image.

Endocrine therapy. Aromatase inhibitors cause severe vaginal dryness and dyspareunia — often more than chemotherapy — plus loss of libido. Tamoxifen has variable effects. Androgen deprivation therapy for prostate cancer causes profound loss of desire, erectile function and often orgasm, plus hot flushes, fatigue and mood change.

Everything. Fatigue, pain, anxiety, depression, altered body image, fear of recurrence, and the shift from being a partner to being a patient.

What helps

Vaginal dryness and stenosis after pelvic treatment. Regular moisturisers, generous lubricant, and vaginal dilator use started early after radiotherapy to prevent stenosis — this is preventive, and prevention is far easier than treatment. Topical vaginal oestrogen is effective; for hormone-receptor-positive breast cancer it is a specific discussion with the oncologist, and increasingly the position of menopause societies is that low-dose vaginal oestrogen is acceptable for many patients after other options fail, given very low systemic absorption. Non-hormonal options include vaginal DHEA and hyaluronic acid preparations.

Erectile dysfunction after prostate treatment. Penile rehabilitation started early: PDE5 inhibitors, vacuum erection devices, intracavernosal injections, and penile prosthesis where other options fail. Starting early matters — prolonged absence of erection causes fibrotic change and shortening.

Loss of desire on endocrine therapy. Frequently irreversible while on treatment. What helps is redefining intimacy rather than waiting for desire to return: responsive-desire approaches, non-genital touch, and being explicit with a partner about what is medication and what is not.

Fatigue. Pacing, timing intimacy for the best part of the day, and shorter encounters.

Neuropathy and altered sensation. Different pressures, vibration, and mapping what still registers rather than assuming what used to work still does.

Body image. Psychological support has evidence here; so does going slowly, controlling lighting and clothing, and a partner who neither stares at nor conspicuously avoids a scar or stoma.

Fertility

Fertility preservation must be discussed before treatment starts — sperm banking, egg or embryo freezing, ovarian tissue cryopreservation, ovarian transposition before pelvic radiotherapy. This conversation is frequently omitted in the urgency of a diagnosis, and it cannot be recovered afterwards. Ask for it explicitly if it has not been raised.

Safety questions people are afraid to ask

• Sex does not cause cancer to recur or spread.
• Cancer is not transmissible to a partner.
• Sex is generally safe during treatment, with specific exceptions: barriers are advised during and shortly after chemotherapy, since cytotoxic drugs are present in body fluids for a period, typically 48–72 hours depending on the agent; avoid penetration during severe neutropenia or thrombocytopenia because of infection and bleeding risk; and avoid it while a surgical wound is healing.
• Contraception is needed during treatment even where periods stop, since ovulation may still occur, and pregnancy during chemotherapy or radiotherapy carries serious fetal risk.
• Internal radiotherapy (brachytherapy) has specific timing advice; ask the team.

Asking for help

Say the words directly: "Cancer treatment has affected my sex life and I would like help with it." Ask for referral to a psychosexual therapist, a pelvic health physiotherapist, or a specialist survivorship clinic. Many cancer centres have these and do not offer them unprompted. Macmillan, Maggie's, the American Cancer Society and equivalent organisations publish specific guidance and run support services.

Sources

• Carter J et al. "Interventions to address sexual problems in people with cancer: ASCO clinical practice guideline adaptation." Journal of Clinical Oncology, 2018.
• Bober SL, Varela VS. "Sexuality in adult cancer survivors: challenges and intervention." Journal of Clinical Oncology, 2012.
• Faubion SS et al. and The Menopause Society position statements on vaginal oestrogen after breast cancer.
• Salonia A et al. "Sexual rehabilitation after treatment for prostate cancer." Journal of Sexual Medicine, and EAU guidance.
• Miles CL et al. "Vaginal dilator therapy for women receiving pelvic radiotherapy." Cochrane Database of Systematic Reviews.
• Oktay K et al. "Fertility preservation in patients with cancer: ASCO clinical practice guideline update." Journal of Clinical Oncology, 2018.

Last reviewed: August 2026.